Lazard 2024 Global Biopharmaceutical Leaders Study Featured in BioCentury

On September 25, BioCentury published an article highlighting the 2024 Lazard Global Biopharmaceutical Leaders Study. This year's survey results forecast an increase in M&A activity with a rise in innovation, including broader impact from artificial intelligence and machine learning technologies in the biopharma sector.

David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard, offered commentary on the survey's findings and highlighted a cautiously optimistic outlook for the sector, understanding there are existing concerns about economic momentum and geopolitical uncertainty. He noted that the pharmaceuticals industry's need to drive growth, replenish their pipelines, and strengthen franchises, particularly with looming patent cliffs, is a primary driver of bolt-on M&A.

On the significance of advanced technology, David stated, "We were struck by how widely distributed their views were across a wide range of technological modalities, which to us reflects the level of excitement, and the breadth and depth of innovation, within each of these modalities."

Click here to read the full BioCentury article.